文献速递前列腺癌

老年前列腺癌患者持续与间歇性雄激素剥夺治疗的真实世界实践模式及预测因素

Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
PubMed 文献 · J Urol · 2021-05-25

该研究基于加拿大安大略省1997-2017年≥65岁前列腺癌患者数据,评估间歇性雄激素剥夺治疗(IADT)的真实使用情况。共纳入8544例患者,仅16.4%接受IADT,既往局部治疗者升至26.6%。既往局部治疗、高收入、放疗科医生及医生经验丰富与IADT使用增加相关。

要点

  • 老年前列腺癌患者中IADT使用率仅16.4%,既往局部治疗者达26.6%。
  • 放疗科医生比泌尿外科医生更倾向使用IADT(OR 1.99)。
  • 既往局部治疗和高收入与IADT使用增加独立相关。

核心结论

  • 在≥65岁前列腺癌患者中,IADT仍未被充分利用,仅约1/6至1/4的合适患者接受该治疗。
  • 临床、社会人口学和医生特征在治疗选择中起重要作用。

研究设计与样本

  • 基于安大略省1997-2017年≥65岁前列腺癌患者的人群回顾性队列研究。
  • 共纳入8544例开始ADT≥3个月的患者,其中1715例曾接受局部治疗。
  • IADT定义为ADT中断≥6个月(初始)或≥3个月(后续),排除新辅助/辅助治疗。

主要发现

  • 全部患者中16.4%接受IADT,范围从11.4%到24.8% across health-planning regions;既往局部治疗者升至26.6%。
  • 既往局部治疗(OR 1.85, 95% CI 1.59-2.17, p<0.001)和最高收入五分位(OR 1.32, 95% CI 1.08-1.60, p=0.005)增加IADT几率。
  • 放疗科医生比泌尿外科医生更可能使用IADT(OR 1.99, 95% CI 1.59-2.50, p<0.001),执业≥10年医生OR 1.44(95% CI 1.11-1.88, p=0.007)。

关键数值与推荐

  • IADT使用率:全部患者16.4%,既往局部治疗者26.6%。
  • 预测因素:既往局部治疗OR 1.85,最高收入五分位OR 1.32,放疗科医生OR 1.99,医生执业≥10年OR 1.44。

临床怎么用

  • 临床医生应认识到IADT在老年前列腺癌患者中应用不足,尤其泌尿外科医生可考虑在合适患者中增加IADT使用。
  • 治疗决策需综合考虑患者临床特征、社会经济因素及医生专业背景。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • IADT定义基于ADT中断间隔,可能受随访和数据记录影响。
  • 研究仅纳入安大略省≥65岁患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Phase-III randomized control trial evidence suggests intermittent androgen deprivation therapy (IADT) is not significantly inferior to continuous androgen deprivation therapy (ADT) for patients with prostate cancer (PC). However, clinical practice and guidelines differ in their recommendations. We evaluate real-world utilization and practice patterns of IADT. MATERIALS AND METHODS: Ontario men ≥65 years of age with PC who initiated ADT for ≥3 months were identified (1997-2017). Lapses in ADT ≥6 months (initial gap) and ≥3 months (subsequent gaps) were used to classify IADT. Neoadjuvant/adjuvant therapy was excluded. Disease stage adjustment was completed for patients with likely metastatic disease based on de novo presentation with ADT. Patient and physician predictors of IADT were analyzed using multivariable logistic regression. RESULTS: We identified 8,544 patients with 1,715 having previously received local therapy. Among all patients, 16.4% received IADT. This ranged from 11.4%-24.8% across health-planning regions and increased to 26.6% in those with previous local therapy. Mean followup was 8.3 years. Patients with prior local therapy (OR 1.85, 95% CI 1.59-2.17, p <0.001) and those in the highest income quintile (OR 1.32, 95% CI 1.08-1.60, p=0.005) had increased odds of receiving IADT. Radiation oncologists were more likely to use IADT than urologists (OR 1.99, 95% CI 1.59-2.50, p <0.001), as were physicians with more experience (≥10 years in practice: OR 1.44, 95% CI 1.11-1.88, p=0.007). In specialty-stratified analyses, case volume was significantly associated with IADT for radiation oncologists (highest quartile: OR 1.73, 95% CI 1.14-2.62, p=0.009). CONCLUSIONS: IADT remains underutilized for patients with PC who ≥65 years of age with only 1 in 4 to 1 in 6 eligible patients receiving this form of care. Clinical, sociodemographic and physician characteristics play an important role in treatment selection.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Cheung DC, Alibhai SMH, Martin LJ, et al. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men. J Urol. 2021. PMID: 34032504. doi:10.1097/JU.0000000000001876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。